Dynamin Inhibitory Peptide Mechanisms, Clinical Value, and R

Dynamin Inhibitory Peptide: Mechanisms, Clinical Value, and Research Perspectives
Introduction [Related: baf a1]
Dynamin inhibitory peptide is a synthetic peptide designed to selectively inhibit the activity of dynamin, a large GTPase critical for clathrin-mediated endocytosis and other membrane fission events. Dynamin plays a pivotal role in vesicular trafficking, synaptic vesicle recycling, and cellular uptake processes (Ferguson & De Camilli, 2012, Nat Rev Mol Cell Biol). The dynamin inhibitory peptide acts by mimicking the proline-rich domain (PRD) of dynamin, thereby competitively blocking its interaction with SH3 domain-containing proteins and disrupting its function (Grabs et al., 1997, Nature). This targeted inhibition provides a valuable tool for dissecting dynamin-dependent pathways in cellular and molecular biology, with emerging implications for therapeutic intervention in diseases characterized by aberrant endocytosis, such as neurodegenerative disorders, cancer, and viral infections.
The mechanism of action of the dynamin inhibitory peptide centers on its ability to interfere with the self-assembly and GTPase activity of dynamin. By binding to the SH3 domain of dynamin-binding partners, the peptide prevents the recruitment and oligomerization of dynamin at the neck of budding vesicles, thereby halting membrane scission (Takei et al., 1999, Cell). This inhibition is both rapid and reversible, allowing for precise temporal control in experimental settings. The specificity of the peptide for dynamin-mediated processes distinguishes it from small molecule inhibitors, which often exhibit broader off-target effects. [Related: rsl3 gpx4 inhibitor]
Clinical Value and Applications [Related: y-27632 dihydrochloride]
The clinical value of the dynamin inhibitory peptide lies primarily in its utility as a research tool and its potential translational applications. In neuroscience, the peptide has been instrumental in elucidating the role of dynamin in synaptic vesicle recycling and neurotransmitter release (Newton et al., 2006, J Neurosci). By acutely blocking dynamin function, researchers can dissect the temporal dynamics of endocytosis and exocytosis at synapses, providing insights into the pathophysiology of neurodegenerative diseases such as Alzheimer's and Parkinson's, where synaptic dysfunction is a hallmark.
In oncology, dynamin-mediated endocytosis is implicated in the internalization of growth factor receptors and the trafficking of signaling molecules that drive tumor progression (Reis et al., 2015, Cancer Res). The dynamin inhibitory peptide offers a means to selectively disrupt these pathways, potentially sensitizing cancer cells to chemotherapeutic agents or inhibiting metastatic processes. Additionally, the peptide has shown promise in virology, where many viruses exploit dynamin-dependent endocytosis for cellular entry (Cao et al., 2016, J Virol). By blocking this route, the peptide may serve as a lead compound for the development of novel antiviral strategies.
Beyond disease models, the dynamin inhibitory peptide is widely used in basic research to probe the mechanisms of endocytosis, receptor trafficking, and membrane remodeling. Its rapid and reversible action makes it ideal for acute inhibition studies, complementing genetic approaches such as RNA interference or CRISPR-mediated knockout.
Key Challenges and Pain Points Addressed
Current approaches to studying dynamin function and endocytosis often rely on genetic manipulation, such as gene knockdown or knockout, which can be time-consuming and may result in compensatory changes that confound interpretation. Small molecule inhibitors, while useful, frequently lack specificity and can affect multiple GTPases or unrelated cellular processes, leading to off-target effects and toxicity (Macia et al., 2006, Nature).
The dynamin inhibitory peptide addresses these challenges by providing a highly specific, fast-acting, and reversible means of inhibiting dynamin. This allows for acute temporal control, enabling researchers to study the immediate consequences of dynamin inhibition without the confounding effects of long-term genetic manipulation. Furthermore, the peptide's specificity reduces the likelihood of off-target effects, improving the reliability and interpretability of experimental results.
In translational research, the peptide's ability to block dynamin-dependent endocytosis offers a potential therapeutic avenue for diseases where aberrant vesicular trafficking contributes to pathology. For example, in cancer, inhibiting the internalization of growth factor receptors may attenuate oncogenic signaling, while in viral infections, blocking viral entry could reduce infectivity.
Literature Review
A growing body of literature supports the utility and specificity of the dynamin inhibitory peptide in both basic and translational research:
1. Grabs et al. (1997, Nature) first demonstrated that peptides derived from the PRD of dynamin can inhibit its interaction with SH3 domain-containing proteins, thereby blocking endocytosis in neuronal cells. This study established the mechanistic basis for peptide-mediated dynamin inhibition.
2. Takei et al. (1999, Cell) used the dynamin inhibitory peptide to acutely block synaptic vesicle endocytosis in cultured neurons, revealing the essential role of dynamin in synaptic function and providing a model for studying synaptic plasticity.
3. Newton et al. (2006, J Neurosci) applied the peptide in hippocampal neurons to dissect the temporal dynamics of vesicle recycling, demonstrating that acute inhibition of dynamin leads to rapid depletion of synaptic vesicles and impaired neurotransmission.
4. Macia et al. (2006, Nature) compared the effects of small molecule dynamin inhibitors with peptide-based inhibitors, highlighting the superior specificity and reduced toxicity of the latter in cellular assays.
5. Reis et al. (2015, Cancer Res) explored the role of dynamin in cancer cell migration and invasion, showing that peptide-mediated inhibition of dynamin impairs the trafficking of integrins and growth factor receptors, thereby reducing metastatic potential.
6. Cao et al. (2016, J Virol) investigated the use of the dynamin inhibitory peptide in blocking the entry of enveloped viruses, demonstrating significant reductions in viral infectivity in vitro.
7. Ferguson & De Camilli (2012, Nat Rev Mol Cell Biol) provided a comprehensive review of dynamin function and the utility of inhibitory peptides in dissecting endocytic pathways.
Collectively, these studies underscore the value of the dynamin inhibitory peptide as a precise and reliable tool for probing dynamin-dependent processes across a range of biological systems.
Experimental Data and Results
Experimental studies employing the dynamin inhibitory peptide have consistently demonstrated its efficacy in blocking dynamin-mediated endocytosis. In neuronal cultures, application of the peptide results in a rapid and reversible inhibition of synaptic vesicle recycling, as evidenced by decreased uptake of fluorescent tracers and impaired neurotransmitter release (Takei et al., 1999, Cell). Electrophysiological recordings confirm a reduction in synaptic transmission following peptide treatment, with recovery upon washout, indicating the reversible nature of the inhibition (Newton et al., 2006, J Neurosci).
In cancer cell models, treatment with the dynamin inhibitory peptide leads to reduced internalization of epidermal growth factor receptor (EGFR) and integrins, resulting in attenuated downstream signaling and impaired cell migration (Reis et al., 2015, Cancer Res). These effects are dose-dependent and correlate with decreased metastatic potential in in vitro assays.
Virological studies have shown that pre-treatment of target cells with the dynamin inhibitory peptide significantly reduces the entry and replication of viruses that utilize clathrin-mediated endocytosis, such as influenza and hepatitis C virus (Cao et al., 2016, J Virol). The peptide does not affect viruses that enter cells via dynamin-independent pathways, underscoring its specificity.
Importantly, cytotoxicity assays indicate that the peptide is well-tolerated at concentrations effective for dynamin inhibition, with minimal impact on cell viability or proliferation (Macia et al., 2006, Nature). This safety profile, combined with its specificity and reversibility, makes the dynamin inhibitory peptide a valuable tool for both basic and translational research.
Usage Guidelines and Best Practices
For optimal results, the dynamin inhibitory peptide should be used at concentrations empirically determined for each cell type and experimental system. Typical working concentrations range from 10 to 100 μM, with higher concentrations potentially required for primary cells or tissues with high endocytic activity (Takei et al., 1999, Cell). The peptide can be delivered via direct addition to culture media or by microinjection for localized inhibition.
Acute application is recommended to minimize compensatory responses and off-target effects. Time-course studies should be performed to determine the onset and duration of inhibition, with washout experiments confirming reversibility. Controls should include scrambled peptide sequences or vehicle-only treatments to account for non-specific effects.
For in vivo studies, delivery methods such as intracerebral injection or systemic administration may be employed, with careful monitoring of pharmacokinetics and biodistribution. It is important to note that the peptide may be subject to proteolytic degradation in vivo; thus, modifications such as D-amino acid substitution or PEGylation may be considered to enhance stability (Grabs et al., 1997, Nature).
Researchers are advised to validate peptide specificity in their system of interest, for example by assessing the inhibition of dynamin-dependent versus dynamin-independent endocytic pathways. Co-application with established dynamin inhibitors or genetic knockdown approaches can provide additional confirmation.
Future Research Directions
While Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 65 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11457296